Tag: FirstLine

Gastroenterology

Pembrolizumab Gets First-Line Indication for mCRC

Newsemia
(MedPage Today) — WASHINGTON — The FDA approved the PD-1 inhibitor pembrolizumab (Keytruda) as initial treatment of metastatic, mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) colorectal...
Gastroenterology

Comparison of efficacy and health-related quality of life of first-line haploidentical hematopoietic stem cell transplantation with unrelated cord blood infusion and first-line immunosuppressive therapy for acquired severe aplastic anemia

Newsemia
Comparison of efficacy and health-related quality of life of first-line haploidentical hematopoietic stem cell transplantation with unrelated cord blood infusion and first-line immunosuppressive therapy for...
Gastroenterology

The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials

Newsemia
The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials Source link...
Latest News

First-line psychotherapies show limited effectiveness for treating military-related PTSD

Newsemia
A review of recent clinical trials paints a sobering picture of the usefulness of first-line psychotherapies in treating active duty military personnel and veterans with...
Gastroenterology

First-Line IO Yields Long Survival in MSI-H/dMMR Colon Cancer

Newsemia
<![CDATA[]]>(MedPage Today) — SAN FRANCISCO — The scientific program of the Gastrointestinal Cancers Symposium included more than 800 abstracts over the three days of the...
Pharma / Biotech

Oral vinorelbine versus intravenous vinorelbine, in combination with epirubicin as first-line chemotherapy in Chinese patients with metastatic breast cancer.

Newsemia
Related Articles Oral vinorelbine versus intravenous vinorelbine, in combination with epirubicin as first-line chemotherapy in Chinese patients with metastatic breast cancer. Cancer Chemother Pharmacol. 2019...
Latest News

Takeda Presents Long-Term Data in ALK+ NSCLC Showing ALUNBRIG® (brigatinib) Continues to Demonstrate Superiority in the First-Line After Two Years of Follow-Up

Newsemia
CAMBRIDGE, Mass. & OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced updated data from the Phase 3 ALTA-1L trial, which evaluated ALUNBRIG versus crizotinib...
Pharma / Biotech

A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-line Treatment for EGFR-mutation Positive NSCLC Patients.

Newsemia
Related Articles A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-line Treatment for EGFR-mutation Positive NSCLC Patients. J...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World